Veeva Systems is trading at $311.02, up 4.60%, as investors focused on IQVIA making Veeva’s clinical applications enterprise standards across its studies and adoption by 175+ biotechs.
- Oppenheimer reiterated Outperform, a $325 target, and called Veeva a “Best Idea.”
- Veeva also announced a November 5 Investor Day.
- The rally defied weakness in software and broader technology amid inflation and interest-rate concerns, according to the reported news page.